Project Grant DP2CA311215
Award Date 8/1/25
Completion Date 7/31/28
Dollars Obligated $0
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
- This $421,685 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research conducted by the University of California, San Francisco (UCSF) to investigate the "reactive" immune system in tumors and the tumor microenvironment. The study aims to discover discrete immune cell niches within the tumor that can enhance the effectiveness of cancer immunotherapies. Using innovative spatial transcriptomics, genetic tools, and cellular...
- This federal Project Grant award of $677,787 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of California, San Francisco (UCSF) to study the role of AIRE-expressing macrophages in tumor immune evasion. The research aims to define novel mechanisms by which tumors evade immune responses, with a focus on the function of these unique macrophage populations in the tumor microenvironment. The project will run from August 2025 through...
- This federal Project Grant award of $680,598 from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) supports research to understand the role of the Cullin-5 complex in regulating T cell dysfunction in cancer. The research aims to develop new therapeutic approaches to engineer T cells with durable effector function, by targeting the Cullin-5 complex to prevent T cell dysfunction caused by chronic tumor antigen stimulation. The award was provided to the...
- This federal Project Grant award of $640,522 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to The Leland Stanford Junior University supports research to elucidate how microbial microproteins modulate macrophage function, a critical coordinator of tumor immune response. The project aims to carry out high-throughput screens of thousands of microbial macromolecules to identify those that directly modulate macrophages, with the goal of enhancing cancer immunotherapy...
- This federal Project Grant award, valued at $641,936 and funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), aims to develop novel strategies to program tumor-associated neutrophils as antitumor effector cells for the treatment of glioblastoma (GBM), the most aggressive type of brain cancer. The project will leverage synthetic biology, machine learning, and next-generation sequencing to interrogate tumor-associated neutrophils and develop methods to reprogram...
- This $156,276 federal Project Grant award was provided by the National Cancer Institute under the Cancer Research Manpower (CFDA 93.398) program. The funding supports research aimed at decoding therapeutic tumor antigens and understanding how dendritic cells contribute to anti-tumor T cell immunity, with a focus on pancreatic cancer. Key objectives include comparing tumor immunopeptidomes presented by cancer cells versus dendritic cells, and evaluating the impact of regulatory T cells on...
- The U.S. National Cancer Institute (NCI) awarded a Project Grant under the Cancer Research Manpower program (CFDA 93.398) to The Johns Hopkins University to conduct a comparative analysis of the effects of M-CSF and GM-CSF on human monocyte metabolic reprogramming and differentiation into tumor-associated macrophage-like cells. The $162,486 award, effective from January 8, 2025 through August 31, 2027, aims to improve the understanding of how the cytokines M-CSF and GM-CSF differentially...
- This federal Project Grant award of $663,340 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to elucidate the mechanisms by which the ablation of intratumoral regulatory T cells can mobilize NK cells and CD4 T cells to control MHC I-deficient tumors. The research aims to determine how CD4 T cell help enhances the antitumor function of NK cells, including the role of cytokines like IL-2 and IL-15, as well as test whether intratumoral Treg depletion...
- This federal Project Grant award of $222,998.00 from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research at the University of California, San Diego (UCSD) to develop a novel virus-like particle (VLP) vector for engineering endogenous immune cells to express chimeric antigen receptors (CARs). The goal is to enable these engineered immune cells, including T cells, NK cells, and macrophages, to mediate potent killing of ovarian cancer cells. This...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $282,053 to The Regents of the University of California, San Francisco (UCSF) to support research aimed at understanding how liver disease impacts myeloid cells and drives immunotherapy resistance in hepatocellular carcinoma. The 5-year award, starting on March 1, 2025, will fund experiments to examine immunosuppressive myeloid cells in viral and non-viral hepatitis, use...